Everolimus in the Treatment of Advanced Gastroenteropancreatic Neuroendocrine Neoplasm: A Single-Center Retrospective Study in China
#1454
Introduction: Everolimus showed antitumor activity in patients with advanced pancreatic neuroendocrine tumors in a phase III clinical trial, but data in Chinese patients was limited.
Aim(s): To determine the safety and efficacy of everolimus in Chinese patients with advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs).
Materials and methods: A total of 15 patients who were treated with everolimus between November 2013 and December 2015 were evaluated for adverse events and tumor responses retrospectively.
Conference: 13th Annual ENETSConcerence (2016)
Presenting Author: Chen J
Authors: Zhang Y, Chen L, Chen M, Chen J,
Keywords: gastroenteropancreatic neuroendocrine neoplasm,everolimus, treatment,
To read the full abstract, please log into your ENETS Member account.